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We have just celebrated the 50th anniversary of mandatory
newborn screening (NBS). Beyond any question, NBS has
been a huge success. It has virtually eliminated the tragedy
of intellectual disability from phenylketonuria (PKU) and
congenital hypothyroidism in the developed world. It has
eliminated death or profound neurologic sequelae from
neonatal sepsis in galactosemia and in salt-wasting congen-
ital adrenal hyperplasia and sickle cell disease. The clinical
complications of biotinidase deﬁciency are now rarely
encountered. Sudden death from the fatty acid oxidation
disorders is almost a thing of the past. Children with hom-
ocystinuria and maple syrup urine disease can achieve their
full potentials and grow into productive adults.
If this can be accomplished for the metabolic and endo-
crine disorders, could there be even greater beneﬁt from
NBS for genetic disorders in general, including nonmeta-
bolic genetic disorders? True, we do not have preventive
therapies for chromosomal aberrations or most other
genetic abnormalities but there could be many other bene-
ﬁts from neonatal diagnosis, such as information for the
family to prepare for progressive disability in the child, for
genetic counseling for family planning, for prenatal or pre-
conceptual diagnosis in future pregnancies, for prevention
of needless and expensive diagnostic odysseys in the child,
and still other potential beneﬁts (Landau et al. 2014).
So, why not expand NBS into genetic screening? This
probably can be done. Next-generation sequencing (NGS)
could allow examination of the entire genome. The cost
of the sequencing is rapidly decreasing and may soon be
low enough to accommodate NBS. Potentially, every
genetic alteration could be identiﬁed within a few days
after birth by testing the current NBS specimen or per-
haps even earlier by screening umbilical cord blood. If
screening included identiﬁcations of variations considered
to increased risk for common diseases such as cancer,
Alzheimer’s disease, or Parkinson’s, the infant would also
be a proxy for family members leading to their testing for
at-risk variations. Newborn genetic screening sounds like
a “no-brainer.”
Unintended Consequences of Current
NBS
While it is true that NBS has led to signiﬁcant beneﬁt in
the diagnosis and treatment of many disease, it is also
true that current NBS has serious unintended conse-
quences (Wilcken 2013). From its very beginning, as a
method that led to presymptomatic diagnosis and preven-
tive treatment for one disorder, PKU, overdiagnosis, and
overtreatment has been an issue (Paul and Brosco 2013).
For instance, when NBS for PKU began, it was assumed
that every infant with an elevated phenylalanine level had
PKU and required dietary therapy. Within a few years,
however, this was shown not to be true; some of these
infants had a variant of PKU characterized by a lower
level of hyperphenylalanemia and did not require therapy
(Kennedy et al. 1967). As NBS evolved overdiagnosis and
unnecessary treatment has substantially increased, espe-
cially so with the relatively recent addition of expanded
NBS by tandem mass spectrometry (MS/MS). Instead of
this happening in one or two disorders, it is now occur-
ring in many disorders (Wilcken 2013).
As an example, medium chain acyl-CoA dehydrogenase
deﬁciency (MCADD) has been known to result in sudden
death. Consequently, every infant found by NBS to have
any increase in octanoylcarnitine (C8), the major bio-
chemical marker for MCADD, is assumed to be at risk
for sudden death. However, the available C8 levels in chil-
dren with MCADD who suddenly died have always been
markedly elevated, suggesting that the risk of sudden
death may only apply to infants in whom the C8 level in
NBS is unusually high (Yusupov et al. 2010). Neverthe-
less, attention is called to infants found by NBS to have
even very low elevations of C8 and many are “medical-
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81ized” by metabolic follow-up and treatment. In our center
we are seeing more cases of several other metabolic
disorders since expanded NBS began than came to clinical
attention prior to NBS. NBS for galactosemia is another
example. Most infants with a positive NBS result have a
benign variant of galactosemia known as the Duarte/
galactosemia genetic compound (Levy et al. 1978; Ficicio-
glu et al. 2008). Nevertheless, these infants are usually
referred to metabolic centers where expensive conﬁrma-
tory testing may be performed and some unnecessarily
treated with a lactose-free diet (Ficicioglu et al. 2008).
The story of benign variants identiﬁed in NBS continues
through very long chain acyl-CoA dehydrogenase deﬁ-
ciency (VLCADD), isovaleric acidemia (IVA), congenital
hypothyroidism, and most likely every disorder screened
(Vockley and Ensenauer 2006; Ensenauer et al. 2004).
Beyond these likely benign variants, several entire dis-
orders identiﬁed in NBS are likely benign. These disorders
are among the most frequently identiﬁed in NBS and
include short chain acyl-CoA dehydrogenase deﬁciency
(SCADD), a fatty acid oxidation disorder (Waisbren et al.
2008), methionine adenosyltransferase (MATI/III) deﬁ-
ciency (Mudd et al. 1995), isobutyryl-CoA dehydrogenase
deﬁciency (12), and 3-methylcrotonyl-CoA carboxylase
deﬁciency (3-MCCD) (Landau and Levy, unpubl. data).
Infants with the NBS abnormality suggesting these
disorders, however, are usually referred to a metabolic
center where conﬁrmatory testing is performed and are
often followed up for several years with medical visits and
laboratory tests as well as treatment.
None of these unintended consequences are reasons to
conclude that NBS has been a net negative. As mentioned
at the outset of this commentary, NBS has been an
extraordinarily positive force in the prevention of tragedy
from many disorders. They are reasons, however, to be
very cautious in expanding NBS into “genetic screening.”
Even with caution we can be certain that there will be
unintended consequences. Without careful and intelligent
planning, the consequences could be extremely disruptive
to many families. With informed planning, the negative
consequences could be minimized so that newborn genetic
screening could be a very positive force in medicine.
What is Meant by Genetic NBS?
The current blood specimen collected from the heel of
the newborn infant or blood collected from the umbilical
cord would be tested by whole exome sequencing (WES)
or whole genome sequencing (WGS), presumably within
current NBS programs. Should some NBS laboratories
not be capable of this highly sophisticated testing, as is
very likely, the NBS program could contract out genetic
screening to medical centers or private laboratories with
this capability. Genetic variations considered to have clin-
ical signiﬁcance would be reported to the medical care
provider or to a genetic center leading to evaluation of
the infant. Many more genetic disorders than the current
25–30 metabolic disorders would be covered. These would
include additional metabolic disorders such as the Smith–
Lemli–Opitz (SLO) syndrome, the congenital disorders of
glycosylation (CDG), and others. Genetic screening would
also expand NBS into nonmetabolic genetic disorders
such as chromosomal abnormalities, neuroﬁbromatosis,
Duchenne muscular dystrophy, tuberous sclerosis, and
many others (Table 1). The clinical phenotype might be
apparent at birth or within the ﬁrst weeks or months of
life, or maybe later in onset, appearing in childhood or
the adult years. Treatment might consist of a speciﬁc
therapy that could beneﬁt the infant or information could
be provided to the family about the potential for recur-
rence that might inﬂuence future family planning. Genetic
variations that indicate a certain degree of risk for com-
mon diseases such as cancer, diabetes, cardiomyopathy,
or Parkinsonism might also be reported leading to genetic
and clinical evaluation of family members.
The extent to which genetic variations might be
reported would have to be determined prior to the initia-
tion of genomic sequencing. One plan could be to exam-
ine only those areas of the genome in which there could
be variations considered “actionable.” The “actions” could
include therapy or diagnosis so as to avoid medical odys-
seys or information upon which the family may act (Berg
et al. 2011). The remaining sequences could be masked or
variations in them could be identiﬁed but not reported.
This latter information could be deleted or could be
stored for future recovery should there be a clinical need.
Another plan could “open up” the sequencing so that all
variations believed to possibly be of clinical signiﬁcance
Table 1. A brief sample of the additional genetic disorders potentially
identiﬁable by genomic sequencing in newborn screening.
Disorder Treatment
Other potential
beneﬁt
Smith–Lemli–Opitz syndrome Cholesterol Family planning
1
Duchenne muscular dystrophy Drug (?) Patient planning
Family planning
Congenital disorders of
glycosylation
None
2 Family planning
Neuroﬁbromatosis None Patient planning
Family planning
Wilson disease Penicillamine Family planning
Menkes disease Copper Family planning
Lysosomal storage disorders Enzyme Family planning
1Family planning includes prenatal or pre-implantation diagnosis.
2The exception is type 1b in which mannose therapy may be very
effective.
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to be pathological as well as variations in which the
evidence for disease association is equivocal. This plan
would also include all variations that are believed to indi-
cate a higher than average risk for late onset common
diseases as well as many others.
The Potential for Unintended
Consequences in Genetic NBS
Should NBS be expanded into genetic screening? It is cer-
tain that unintended consequences will occur, some likely
to be quite serious. The sequencing is unlikely to be
totally reliable and errors will almost certainly occur (Zhu
and Xiong 2012). Depending on the sequencing platform
used, some variations will be missed (Clark et al. 2011),
potentially depriving an infant of early diagnosis and ame-
liorative or preventive therapy. Interpretation will vary
among screening laboratories, one program assigning a
variation as a pathological mutation and another program
considering the variation inconsequential. This will derive
from the uncertainty of many genetic variants as causal of
disease, an uncertainty that will not only continue but
likely increase as routine genetic screening identiﬁes a
great many more variants than are now known (Cooper
and Shendure 2011). This inconsistency in assigning cau-
sation of disease to genetic variants will likely result in
both underdiagnosis and overdiagnosis of disease. Even
when there is certainty that a variant is associated with a
known disorder the consequences of the variant, within
the disorder or even the consequences of the disorder
itself, may be unclear. This has plagued the recent expan-
sion of metabolic disorders in NBS and will surely be
increased by genetic NBS (Clayton 2010; Wilcken 2012).
A major concern is the possibility that some parents
might opt out of NBS entirely from their general opposi-
tion to DNA examination or fear that the detection of
genetic variations in their newborn will jeopardize obtain-
ing health insurance or life insurance, or even school
acceptance and future employment (Landau et al. 2014).
This would have tragic consequences for an infant with
PKU or congenital hypothyroidism or any other disorder
in which presymptomatic therapy would prevent the
abnormal phenotype. Very few parents opt out of current
NBS but the likely requirement of informed consent for
genetic screening could threaten universal NBS.
Challenges of Incorporating Genetic
Screening into NBS
Could genetic screening become incorporated into the
NBS of today? What are the implications for medical and
clinical genetic follow-up of genetic NBS? It is unlikely
that the current public health-related NBS laboratories,
with very few possible exceptions, will be able to perform
and interpret NGS. Consequently, a new structure for
NBS will be required, likely a two-tiered approach in
which the current NBS laboratories would continue to
perform the mandated NBS and other laboratories would
perform genetic NBS. This will then require either sharing
of the NBS specimen or a second NBS specimen which
will be either cord blood collected on ﬁlter paper or
another blood collected from the heel of the infant.
Genetic NBS will almost certainly require informed con-
sent. Who would provide the complicated genetic infor-
mation to the parents that truly informed consent will
require? Will this be the responsibility of the nurses or
the attending physicians? If so, will they have the time
and knowledge sufﬁcient for this purpose? Will genetic
counselors perform this service? If so, they would only be
available at medical centers and not at the many more
smaller hospitals where most babies are born. Would a
descriptive brochure be sufﬁcient for informed consent? If
so, would most parents have the time and the back-
ground to understand the genetic information? At the
very least, genetic NBS would impose major new obliga-
tions upon NBS and on the hospitals.
Follow up of NBS ﬁndings is a major requirement of
NBS (AAP Newborn Screening Task Force 2000). Infants
with signiﬁcant ﬁndings in current NBS are usually evalu-
ated at medical centers with conﬁrmatory testing. This
requires biochemical analyses and may also require geno-
typing (Landau et al. 2014). Findings in genetic NBS
would likely require medical genetic evaluation with
conﬁrmatory sequencing as well as additional testing.
Given the many newborn infants who could be referred
for genetic evaluation, this could overwhelm the existing
complement of medical geneticists and signiﬁcantly
increase the already very high costs of medical care.
Inevitability of Genetic NBS
Despite all of the potential difﬁculties, genomic sequencing
to one degree or another will eventually be incorporated
into NBS. Studies show that parents are interested in
genetic screening of their newborns (Goldenberg and Sharp
2012). Before incorporation into universal NBS genetic
screening will likely be limited to those relatively few areas
of the genome wherein genes associated with known
actionable disorders reside. Incidental ﬁndings and at-risk
variations would not be reported. It will also likely begin
by being offered as a supplement to mandated NBS only in
medical centers with the complement of staff that can pro-
vide the appropriate information required for informed
consent and in areas where medical genetic follow-up can
be obtained. Genetic screening will likely be considered
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consents will be assessed an additional charge for neonatal
care since neither insurance nor the hospitals are likely to
cover it, although some hospitals might offer this without
additional charge as an inducement for families to deliver
there. Medical centers and free-standing private genetic
laboratories will compete for this service and many private
laboratories will solicit online for this additional NBS.
Any genetic NBS raises many questions of feasibility,
effectiveness, and, certainly not least, ethics and the
medico-legal. The National Institute of Child Health and
Development (NICHD) is currently funding four 5-year
research projects to examine the application of NGS to
NBS (http://www.nih.gov/news/health/sep2013/nhgri-04.
htm, accessed 29 January 2014). Each of these projects is
to examine technical feasibility in applying genomic
sequencing to NBS, to test the medical effectiveness of
sequencing in a neonatal setting, and to address the ethi-
cal, legal and societal implications of sequencing in NBS.
One would hope that genetic sequencing in the newborn
would wait until these projects have been completed and
the results become known.
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